INTRODUCTION
The pathophysiology of spinal cord injury (SCI) comprises both the initial mechanical insult and secondary damage caused by inflammation, hypoxia and excitotoxicity. 1, 2 Attempts have been made to establish an efficient therapeutic protocol either to reduce the tissue damage by preventing secondary damage or to restore the neural tissue. It has been accepted that such intervention would be more efficient at an early time point after injury rather than during the chronic stage. 3 Therefore, many pharmacological and tissue-engineering therapies are now designed to be applied within the first month after injury. 4, 5 One of the obstacles against the innovation of novel therapies for SCI is the difficulty of determining the baseline severity of the injury. During the early period after injury when novel therapies would be applied, unstable conditions of patients, including the phenomenon of spinal shock, prevent precise evaluation of neurological status. 6 Therefore, a novel system that evaluates markers other than neurological symptoms would be expected to increase the accuracy of the initial evaluation of severity. One of the ways is to assess the amount of tissue damaged by traumatic insult. 7 Because the central nervous tissue releases various structural proteins into the cerebral spinal fluid or peripheral blood flow upon trauma, attempts have been made to measure the concentration of a specific protein in samples of blood or cerebrospinal fluid after SCI. [8] [9] [10] [11] However, the utility of any proteins from blood samples as biomarkers for evaluating the severity of SCI patients has not yet been confirmed. A recent report by Shaw et al. 12 introduced a novel biomarker, the phosphorylated form of the highmolecular-weight neurofilament subunit NF-H (pNF-H). As pNF-H is one of the structural proteins of axon fibers that are not detectable in blood of healthy animals, elevation of this protein in blood implies the breakdown of axons. Ueno et al. 13 reported the correlation between plasma pNF-H level at 3 days after injury and hind-limb functions at 4 weeks after injury in the rat contusion model. Regarding human patients, pNF-H level in blood has been reported to be elevated in patients with subarachnoid hemorrhage, traumatic brain injury and amyotrophic lateral sclerosis. [14] [15] [16] However, pNF-H has not been evaluated in a series of human patients with SCI.
In this report, we attempted to measure pNF-H in peripheral blood from patients with SCI, as a pilot study. Our primary aims were to determine whether (1) pNF-H is detectable in blood samples of patients with SCI and (2) the pNF-H level reflects the severity of the injury.
METHODS Patients
We performed a cross-sectional study at a trauma and critical care medical center, and a research institute after obtaining approval from both institutional ethical review boards. Patients with traumatic cervical SCI dating from October 2009 were included in this study. We performed initial physical examination within 12 h after injury and followed up to at least 30 days from admission. Patients whose radiographic examination confirmed intracranial hemorrhage were excluded.
Samples
Blood samples of 5 ml were collected at 6, 12, 18, 24, 48, 72 and 96 h, and 6, 8, 10, 14 and 21 days after the injury. Some samples were not collected at several time points. The plasma samples were collected after centrifugal separation, then frozen and stored until assay.
Clinical evaluation
The severity of neurological impairment was graded according to the American Spinal Injury Association impairment scale (AIS) by trained medical doctors. We confirmed that sacral-sparing was absent in the patients classified as AIS A. After the initial evaluation, the assessment was performed 7 and 30 days after injury. After discharge from the hospitals, the symptoms of patients were followed at an outpatient clinic. In some cases, their symptoms were confirmed by telephone interview by the doctors.
Assay of pNF-H
The pNF-H assay was carried out with a commercially available enzyme-linked immunosorbent assay kit (Human Phosphorylated Neurofilament H ELISA; BioVendor, Modrice, Czech Republic). The frozen plasma samples were allowed to thaw and were then diluted threefold with a dilution buffer. The assay was performed according to the manufacture's protocol. The standard curve was constructed by plotting the mean absorbance of the standards against the known concentration of the standards on a logarithmic scale with the fourparameter algorithm. The concentration of the sample was calculated from the standard curve. Assays for which the pNF-H level exceeded the highest standard (4000 pg ml À1 ) were repeated with more diluted samples. The limit of detection (23.5 pg ml À1 ) was calculated from the mean absorbance of the blank (dilution buffer only) plus three standard deviations of the absorbance of blank. We defined the actual limit of detection as 70 pg ml À1 because the sample was diluted threefold. All samples were tested in duplicate, and the average value of each sample was calculated.
Statistical analysis
Values of pNF-H below the limit of detection (70 pg ml À1 ) were treated as 0 for statistical analysis. For comparison of plasma pNF-H values between AIS C patients and AIS D patients, repeated measure analysis of variance (ANOVA) was used. On the other hand, we used Mann-Whitney's U test to compare pNF-H values of AIS A patients and AIS C patients because variance of pNF-H value in AIS A patients was much larger than that in AIS C patients. We performed a two-sided test, and differences with a P-value of o0.05 were considered statistically significant.
RESULTS
pNF-H was detectable in blood samples of patients with SCI As shown in Table 1 , the average age of the patients was 57. 9 (30-88) years. The follow-up period ranged from 43 to 556 days (average 229.1 days) after injury. At the final follow-up, four patients were classified as AIS A, zero as AIS B, five as AIS C, four as AIS D and one as AIS E. Among 14 cases in the current study, pNF-H was detected (470 pg ml À1 ) in 11 cases within 96 h after injury. Two of pNF-H negative cases were AIS D and the other case was AIS C. The plasma pNF-H levels of four patients who were graded as AIS A at the final follow-up are shown in Figure 1 . In those patients, pNF-H was detectable in plasma from 12 h after injury (221-825 pg ml À1 ), and it increased until 96 h after injury (1919-8023 pg ml À1 ). Thus, pNF-H is detectable in blood samples from patients with severe SCI and the pNF-H value shows increasing pattern in early period.
Plasma pNF-H level was elevated in accordance with the severity of the injury As a biomarker for SCI, one of the expectations for pNF-H is that its concentration should be useful for predicting the prognosis of each patient. Therefore, we investigated if there was a difference in pNF-H levels depending on injury severity. Figure 2a shows average pNF-H values of each AIS grade at each time point from 6 h to 96 h after injury. There is a marked difference between AIS A patients (complete SCI) and AIS C-E patients (incomplete SCI), with statistical significance from 18 h to 96 h after injury between AIS A and AIS C (average pNF-H value at 96 h: AIS A patients, 5260 pg ml À1 ; AIS C patients, 449 pg ml À1 ). In terms of predictive usage of pNF-H, we observed one particular case, Case 11 (AIS C), who was initially evaluated as AIS A on admission and then showed improvement to Plasma pNF-H in SCI patients K Hayakawa et al become AIS C by 7 days after injury. In this 'eventual' AIS C case, we confirmed that the pNF-H value was much lower (86 pg ml À1 at 48 h and 689 pg ml À1 at 96 h after injury) than 'eventual' AIS A patients (Case 5, 9, 12 and 14: ranging from 1210 to 4935 pg ml À1 at 48 h and from 1919 to 8023 pg ml À1 at 96 h after injury). As for less severe SCI, we observed that the pNF-H value tended to be higher in AIS C patients compared with AIS D patients (264 pg ml À1 in average at 96 h), even if not statistically different (Figure 2b ). It should be noted that the only one patient who was graded as AIS E presented relatively high pNF-H value (606 pg ml À1 at 96 h). His symptom was assessed as AIS D with central cord syndrome on admission, and then he recovered to be asymptomatic within 9 months. Taken together, although we did not have any AIS B patients in our series, we assume that plasma pNF-H level is higher in AIS A patients (complete SCI) compared with AIS C-E patients (incomplete SCI), while the significance of pNF-H value in evaluating the severity of incomplete SCI remain undetermined.
Plasma pNF-H level remained elevated up to 21 days after injury
In contrast to the rodent SCI model in which plasma pNF-H decreases after 3 days post injury, we found that pNF-H values in human SCI increase up to 96 h after injury. For a longer period of observation, we collected blood samples from four cases of AIS A and two cases of AIS C up to 21 days after injury. Figure 3 shows pNF-H values of each case, revealing that pNF-H values remained elevated at 21 days after injury in all cases examined. Therefore, we assume that the kinetics of pNF-H are different between human and rodent SCI.
DISCUSSION
In the present pilot study, we analyzed blood samples from 14 patients with cervical SCI. Although the number of the patients and observational period were limited, we found that pNF-H was detectable in patients with SCI and that the pNF-H levels were significantly greater in AIS A patients (complete SCI) compared with AIS C-E patients (incomplete SCI). Therefore, we assume that pNF-H can be regarded as a potential biomarker to assess the severity of SCI.
pNF-H as a biomarker for central nervous system disorders
The present study is the first report of plasma pNF-H measurement in a series of patients with SCI. The striking difference between the rat model and human patients is that the pNF-H values from patients Plasma pNF-H in SCI patients K Hayakawa et al remained elevated even at 21 days after injury, whereas the concentration of pNF-H in the rat has its peak at 3 days and returns to the baseline 14 days after injury. 12 It remains unclear whether the difference is related to different patterns of axonal degeneration between humans and rats or to the difference in the condition of the blood-spinal cord barrier. Sustained elevation of pNF-H has also been reported in studies of subarachnoid hemorrhage and traumatic brain injury. 15, 16 The prolonged elevation of plasma pNF-H in patients with central nervous system disorders suggests the involvement of a continuous axonal degeneration, such as Wallerian degeneration or secondary axonal damage. In either case, it would be safe to conclude that the pNF-H level in blood represents the amount of axonal degeneration as a whole.
Comparison to other biomarkers
There have been several reports on the use of biomarkers to estimate prognosis among patients with SCI. For example, blood levels of S100B and NSE have been measured in experimental SCI. 8, 9, 17 S100B is a calcium-binding protein localized predominantly in astrocytes and Schwann cells, and NSE is a glycolytic enzyme predominantly localized in the cytoplasm of neurons and cells of neuroendocrine lineage. 9 Loy et al. 8 reported that both S100B and NSE present monomodal patterns over time; S100B and NSE have their peak values at 6 h after injury and return to baseline at 24 h. Such rapid changes require accurate timing of blood sampling, which is not always easy in the course of intensive care for SCI. Therefore, one of the favorable characteristics of pNF-H compared with those other markers is that the pNF-H can be stably detected at a later time point. On the other hand, pNF-H is barely detectable at 6 h after injury when S100B and NSE are already elevated in the blood. Taken together, these results suggest it could be beneficial to combine the use of S100B or NSE as 'early markers' and pNF-H as a 'delayed marker' , depending on the type and timing of intervention applied.
Limitations of the current study and future perspectives As the diagnosis is not definitive in the early stages after SCI because of the multiple traumas, sedation, spontaneous recovery etc., it is difficult to prove that a treatment that is administered during this period significantly improves neurological status. Therefore, the ideal biomarker is the one that enables the discrimination of, for example, definite AIS A patients from temporary AIS A patients, who would improve in neurological status with conventional therapies (as we observed in Case 11). Although the current study suggested that pNF-H has a potential for such biomarkers, further case-control studies are required to identify a possible threshold value to discriminate definite AIS A, and then to determine the predictive value of this biomarker. As for incomplete SCI, even though we observe the tendency of higher pNF-H values in AIS C compared with AIS D SCI, one case out of five cases of AIS C patients did not show an increase in pNF-H value. As there is a broad variation in limb functions among AIS C patients, we assume that further studies should include more detailed assessments for clinical symptoms, such as ASIA motor score, Spinal Cord Independence Measure (SCIM) and Walking Index for Spinal Cord Injury (WISCI) with a sufficient length of follow-up period.
Further studies are also required to obtain information about the influence of brain trauma, which may be a concomitant condition in SCI and may obscure the predictive ability of the biomarker. The data of the non-injured patients or patients without neuronal damages are also required to evaluate the specificity of this biomarker. In conclusion, we think the development of useful biomarkers for central nervous system trauma requires the accumulation of precise clinical follow-up data together with determination of the values of a variety of biomarkers in the acute phase.
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